141 results
8-K
EX-99.1
KA
Kineta Inc
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
payment. Revenues in 2022 were due to research and development services from the Genentech Option and License Agreement, which was terminated in December … 2022, and also due to services provided under a grant that was concluded in December 2022.
Research and development (R&D) expense: R&D expenses were
424B3
KA
Kineta Inc
13 Nov 23
Prospectus supplement
5:28pm
preparatory work, the period during which the results of the trials will become available and our research and development programs;
our ability … or recessions that may result from such developments, which could harm our research and development efforts as well as the value of our Common Stock
8-K
EX-99.1
pgs8 u42v2apgtn01l
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
424B5
bj18pieb5izih3
5 Oct 23
Prospectus supplement for primary offering
10:47am
8-K
EX-99.1
bvy3r3d9 37zfx830
11 Aug 23
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-99.1
my2caoy7dt7lozsc142m
29 Jun 23
Kineta to Receive $5 Million Milestone Payment from Merck
7:01am
8-K
EX-99.1
2uvtu9qvo3jhm1t
28 Jun 23
Departure of Directors or Certain Officers
7:00am
424B3
frkkrqtpiv8 gf5nca
12 Jun 23
Prospectus supplement
5:01pm
8-K
EX-99.1
ncrat7
11 May 23
Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update
5:20pm
424B5
hxayb8l2n0f 9mg6qd1
21 Apr 23
Prospectus supplement for primary offering
5:14pm
8-K
EX-99.1
ga45xohl4mzu270r93xo
31 Mar 23
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update
4:03pm